Amendments to the Abstract:

The present invention relates to compounds of the formula (I):



(I)

or a pharmaceutically acceptable salt or solvate thereof, ~~wherein:~~

~~A and B independently represent CH_2 or O, with the proviso that A and B are not simultaneously O;~~

~~Cy represents one of the following~~



~~optionally substituted by one to three groups selected from hydroxy, halogen, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6}haloalkyl, C_{1-6}alkylamino and amino;~~

~~R^1 and R^2 are independently selected from hydroxy, halogen, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6}haloalkyl and C_{3-8}cycloalkyl;~~

~~n represents an integer from 0-4;~~

~~X is hydrogen, hydroxy, halogen or C_{1-6} alkoxy;~~

~~Y is oxy, thio, a 1-4 membered alkylene, a 2-4 membered alkylene ether, 2-4 membered alkylene thioether or an oxyethyleneoxy group, optionally substituted by 1 to 4 groups independently selected from hydroxy, halogen, C_{1-6}alkyl, C_{1-6}alkoxy and C_{1-6}haloalkyl;~~

~~Z is CH or N; and~~

~~p represents an integer from 0-5 when Z is CH or 0-4 when Z is N; when p represents 2 or more, two of R^2s may be taken together with the carbon atoms to which they are attached to form a 5-8 membered cycloalkyl ring~~

to processes for the preparation of, intermediates used in the preparation of, compositions containing such compounds and the uses of such compounds as antagonists of the NMDA NR2B receptor.